Draft:Jeffrey V. Lazarus
| Submission declined on 27 August 2024 by Ktkvtsh (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
Comment: Using Al Jazeera and Financial Times home page as sources is not appropriate. This reads more like a WP:CV than an encyclopedic article. Needs personal information. Where is he from? When was he born? Ktkvtsh (talk) 00:05, 27 August 2024 (UTC)
Professor Jeffrey V. Lazarus MA, MIH, PhD | |
|---|---|
| Born | August 7, 1969 San Francisco, CA |
| Education | BA: New York University (magna cum laude)
MA: Georgetown University (magna cum laude) MIH: Lund University, Sweden PhD: University of Copenhagen |
| Known for | Public health approaches to combat liver disease |
 | Review waiting, please be patient.
This may take 8 weeks or more, since drafts are reviewed in no specific order. There are 1,848 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Jeffrey V. Lazarus is a public health researcher, professor, and advocate whose work addresses the public health policy, epidemiology, and operations challenges presented by major liver health risks.
He is currently professor of global health at the CUNY Graduate School of Public Health and Health Policy in New York City, and research professor and head of the Public Health Liver Group at the Barcelona Institute for Global Health (ISGlobal).
Public Health and Liver Disease
[edit]Liver diseases account for 1 in 25 deaths worldwide.[1] Lazarus’ studies, publications and initiatives have aimed to advance WHO initiatives on “people-centered health systems” and improve prevention, care and treatment for both communicable and non-communicable liver disease.
Viral Hepatitis
[edit]Lazarus has driven significant advancements in prevention, testing, care, and treatment of viral hepatitis across Europe, Africa and the United States.
He co-founded the European Viral Hepatitis Elimination Coalition (ACHIEVE) and contributed to the first WHO viral hepatitis strategy. He also launched the hepatitis C virus (HCV) micro-elimination approach[2] while serving as vice-chair of the European Association for the Study of the Liver (EASL) International Liver Foundation and participated in both Lancet GastroHep commissions on viral hepatitis.[3]
Community-based Model of Care Initiative
[edit]Lazarus and his research team at the Barcelona Institute for Global Health (ISGlobal) have overseen the implementation of the Viral Hepatitis COMmunity Screening, Vaccination, and Care (VH-COMSAVAC) initiative, co-funded by the European Commission and aimed at scaling up and adapting a community-based model of care for hepatitis B virus (HBV) and C testing and linkage to care and HBV vaccination among migrants and refugees.
Steatotic Liver Disease
[edit]Lazarus has contributed key research to the field of steatotic liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).[4] He co-authored the Non-Alcoholic Fatty Liver Disease (NAFLD) public health consensus statement published in Nature Reviews Gastroenterology & Hepatology in 2021,[5] and spearheaded the development of new nomenclature for fatty liver disease published in three major society journals in June 2023.[6] [7] [8] Additionally, he led in the global research priority agenda in the Journal of Hepatology[9] and action priorities in Hepatology,[10] both in 2023.
United Nations General Assembly MASLD/MASH Policy Side-event
[edit]In September 2024, with the support of the Barcelona Institute for Global Health (ISGlobal), Lazarus led the first-ever United Nations General Assembly side-event on MASLD and MASH, titled "MASLD and MASH: prioritizing a global public health threat". It was hosted by the Economist Impact, which launched country-specific policy briefs for Germany, Japan, and the United States.
Current Leadership Roles
[edit]Lazarus is chair of the global Healthy Livers, Healthy Lives coalition.
He co-chairs the Global Think-tank on Steatotic Liver Disease centered around the global research and action priorities in steatotic liver disease.[11][12]
Lazarus also serves on the Editorial Boards of Journal of Hepatology and Liver International.
Awards and Honors
[edit]In 2017, Lazarus received the Economist Intelligence Unit Change Maker Award for contributions to the global elimination of hepatitis C.
In 2023, American Liver Foundation honored Lazarus with the Distinguished Scientific Achievement Award.
In 2024, he was among the Clarivate Highly Cited Researchers.
Finally, in 2024, Lazarus was selected as one of 9 mentors for the EASL Mentorship Programme, which was created to guide young scientists and clinicians through their career paths.
References
[edit]- ^ Devarbhavi, Harshad; Asrani, Sumeet K.; Arab, Juan Pablo; Nartey, Yvonne Ayerki; Pose, Elisa; Kamath, Patrick S. (August 2023). "Global burden of liver disease: 2023 update". Journal of Hepatology. 79 (2): 516–537. doi:10.1016/j.jhep.2023.03.017. PMID 36990226.
- ^ Lazarus, Jeffrey; Safreed-Harmon, Kelly; Thursz, Mark; Dillon, John; El-Sayed, Manal; Elsharkawy, Ahmed; Hatzakis, Angelos; Jadoul, Michel; Prestileo, Tullio; Razavi, Homie; Rockstroh, Jürgen; Wiktor, Stefan; Colombo, Massimo (August 2018). "The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations". Seminars in Liver Disease. 38 (3): 181–192. doi:10.1055/s-0038-1666841. ISSN 0272-8087. PMID 29986353.
- ^ Cooke, Graham S; Andrieux-Meyer, Isabelle; Applegate, Tanya L; Atun, Rifat; Burry, Jessica R; Cheinquer, Hugo; Dusheiko, Geoff; Feld, Jordan J; Gore, Charles; Griswold, Max G; Hamid, Saeed; Hellard, Margaret E; Hou, JinLin; Howell, Jess; Jia, Jidong (February 2019). "Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission". The Lancet Gastroenterology & Hepatology. 4 (2): 135–184. doi:10.1016/S2468-1253(18)30270-X. PMID 30647010.
- ^ Rinella, Mary E.; Lazarus, Jeffrey V.; Ratziu, Vlad; Francque, Sven M.; Sanyal, Arun J.; Kanwal, Fasiha; Romero, Diana; Abdelmalek, Manal F.; Anstee, Quentin M.; Arab, Juan Pablo; Arrese, Marco; Bataller, Ramon; Beuers, Ulrich; Boursier, Jerome; Bugianesi, Elisabetta (December 2023). "A multisociety Delphi consensus statement on new fatty liver disease nomenclature". Journal of Hepatology. 79 (6): 1542–1556. doi:10.1016/j.jhep.2023.06.003. PMID 37364790.
- ^ Lazarus, Jeffrey V.; Mark, Henry E.; Anstee, Quentin M.; Arab, Juan Pablo; Batterham, Rachel L.; Castera, Laurent; Cortez-Pinto, Helena; Crespo, Javier; Cusi, Kenneth; Dirac, M. Ashworth; Francque, Sven; George, Jacob; Hagström, Hannes; Huang, Terry T.-K.; Ismail, Mona H. (January 2022). "Advancing the global public health agenda for NAFLD: a consensus statement". Nature Reviews Gastroenterology & Hepatology. 19 (1): 60–78. doi:10.1038/s41575-021-00523-4. ISSN 1759-5045.
- ^ Schattenberg, Jörn M.; Allen, Alina M.; Jarvis, Helen; Zelber-Sagi, Shira; Cusi, Ken; Dillon, John F.; Caussy, Cyrielle; Francque, Sven M.; Younossi, Zobair; Alkhouri, Naim; Lazarus, Jeffrey V. (2023-01-03). "A multistakeholder approach to innovations in NAFLD care". Communications Medicine. 3 (1): 1. doi:10.1038/s43856-022-00228-y. ISSN 2730-664X. PMC 9810711. PMID 36596859.
- ^ Rinella, Mary E.; Lazarus, Jeffrey V.; Ratziu, Vlad; Francque, Sven M.; Sanyal, Arun J.; Kanwal, Fasiha; Romero, Diana; Abdelmalek, Manal F.; Anstee, Quentin M.; Arab, Juan Pablo; Arrese, Marco; Bataller, Ramon; Beuers, Ulrich; Boursier, Jerome; Bugianesi, Elisabetta (December 2023). "A multisociety Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. ISSN 0270-9139. PMC 10653297. PMID 37363821.
- ^ Lazarus, Jeffrey V.; Anstee, Quentin M.; Hagström, Hannes; Cusi, Kenneth; Cortez-Pinto, Helena; Mark, Henry E.; Roden, Michael; Tsochatzis, Emmanuel A.; Wong, Vincent Wai-Sun; Younossi, Zobair M.; Zelber-Sagi, Shira; Romero-Gómez, Manuel; Schattenberg, Jörn M. (October 2021). "Defining comprehensive models of care for NAFLD". Nature Reviews Gastroenterology & Hepatology. 18 (10): 717–729. doi:10.1038/s41575-021-00477-7. ISSN 1759-5045. PMID 34172937.
- ^ Lazarus, Jeffrey V.; Mark, Henry E.; Allen, Alina M.; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A.; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N.; Burra, Patrizia; Castro-Narro, Graciela E. (September 2023). "A global research priority agenda to advance public health responses to fatty liver disease". Journal of Hepatology. 79 (3): 618–634. doi:10.1016/j.jhep.2023.04.035. PMID 37353401.
- ^ Lazarus, Jeffrey V.; Mark, Henry E.; Allen, Alina M.; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A.; Anstee, Quentin M.; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N.; Burra, Patrizia (February 2024). "A global action agenda for turning the tide on fatty liver disease". Hepatology. 79 (2): 502–523. doi:10.1097/HEP.0000000000000545. ISSN 0270-9139. PMC 10789386. PMID 37540183.
- ^ Lazarus, Jeffrey V.; Mark, Henry E.; Allen, Alina M.; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A.; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N.; Burra, Patrizia; Castro-Narro, Graciela E. (September 2023). "A global research priority agenda to advance public health responses to fatty liver disease". Journal of Hepatology. 79 (3): 618–634. doi:10.1016/j.jhep.2023.04.035. PMID 37353401.
- ^ Lazarus, Jeffrey V.; Mark, Henry E.; Allen, Alina M.; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A.; Anstee, Quentin M.; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N.; Burra, Patrizia (February 2024). "A global action agenda for turning the tide on fatty liver disease". Hepatology. 79 (2): 502–523. doi:10.1097/HEP.0000000000000545. ISSN 0270-9139. PMC 10789386. PMID 37540183.